Muscle HealthGGENCT07502924
Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health
A study testing Geranylgeraniol (150 mg) and Geranylgeraniol (300 mg) in people with Muscle Health and Muscle Strength, run by Lindenwood University at 1 site in United States.
Trial summary
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Read more about this study
- Who is it for?
- Ages 30 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Muscle Health, Muscle Strength, Body Composition
- What is being tested?
- Geranylgeraniol (150 mg) and Geranylgeraniol (300 mg)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Mar 2025to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Between 30 and 60 years old.
- Body mass index values will range from >18.5 and <29.9 kg/m2
- Subject agrees to maintain their existing dietary patterns throughout the study period.
- Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.
- Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week.
- Avoid consumption of pomegranate juice and avoid consumption of CoQ10, vitamin B3 and its precursors, L-carnitine, MK-4
- Subject is willing and able to comply with the study protocol.
- Subject has given voluntary, written, informed consent to participate in the study.
Who cannot join
- BMI <18.5 or > 29.9 kg/m2
- Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV/AIDS), or neurological condition or disease.
- Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.
- History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
- Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
- Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism
Show all 22Show fewer
- Has donated blood in past 60 days
- Diagnosed with or being treated for any endocrinological disorder and/or taking hormone boosting supplements (e.g. herbs) or hormone replacement therapy (prescribed/doctor ordered or not)
- Had CoQ10 supplement in past 30 days. Had steroid medication one month before starting the study
- Currently prescribed for the first time a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) and/or a hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, - Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months
- Current smoker (average of > 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine
- Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to impact energy expenditure or weight loss (caffeine doses <300 mg/day is permissible)
- Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome
- Women who are pregnant, planning to become pregnant, or lactating currently or within the past six months
- Have a known sensitivity or allergy to any of the study products
- History of alcohol or substance abuse in the 12 months prior to screening
- Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol
- Has participated in other clinical trials focused on physical and muscle performance within the last year
- They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study
- Individuals who regularly compete as part of sanctioned athletic activities or those individuals who regularly train more than 360 minutes of exercise per week
- Recent history (<3 months) of exercise training or weight loss (> 5%)
- Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Lindenwood University Exercise and Performance Nutrition Laboratory
Saint Charles, Missouri, 63301
Anthony M Hagele, MS, 636-949-4785, ahagele@lindenwood.edu
Joesi M Morey, MS, jmorey@lindenwood.edu
About this study
Official title: Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscular Strength, Body Composition, Sex Steroid Hormones and CoQ10 Levels in Healthy Men and Women
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.
Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
Read the detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-group trial designed to examine the dose-response effects of geranylgeraniol (GG) supplementation on muscular strength, body composition, aerobic capacity, and physiological biomarkers in healthy, physically active adults.
Approximately 60 men and women aged 30-60 years will be recruited and randomized, stratified by sex, age, and baseline fat-free mass, to receive one of three interventions: placebo, 150 mg GG, or 300 mg GG daily for 8 weeks. All participants and study personnel will remain blinded to group allocation throughout the study.
Participants will complete a screening visit followed by testing visits at baseline (week 0), week 4, and week 8. Assessments will include maximal strength testing (1RM bench press and leg press), muscular endurance (repetitions to failure at a fixed percentage of 1RM), aerobic capacity (VO2peak via graded treadmill test), and body composition using a four-compartment model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy.
Venous blood samples will be collected to assess coenzyme Q10, sex steroid hormones, inflammatory markers, and clinical safety parameters including complete blood count, comprehensive metabolic panel, and lipid profile. Additional outcomes include mood and quality of life assessed via validated questionnaires (POMS and SF-36), dietary intake via 4-day food logs, and fecal samples for metabolomic analysis.
The primary endpoints are changes in maximal strength (1RM leg press and bench press) and fat-free mass from baseline to week 8. Secondary endpoints include changes in muscular endurance, aerobic capacity, body composition variables, biochemical markers, and patient-reported outcomes. Safety will be monitored throughout the study via clinical labs and adverse event reporting.
- Conditions
- Muscle Health, Muscle Strength, Body Composition
- Being tested
- Dietary Supplement - Placebo, Geranylgeraniol (150 mg), Geranylgeraniol (300 mg)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary Supplement - PlaceboDietary supplement
Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Geranylgeraniol (150 mg)Dietary supplement
Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Geranylgeraniol (300 mg)Dietary supplement
Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Comparator | Placebo comparator | Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. Receives: Dietary Supplement: Dietary Supplement - Placebo |
| 150 mg Geranylgeraniol | Active comparator | Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. Receives: Dietary Supplement: Geranylgeraniol (150 mg) |
| 300 mg Geranylgeraniol | Active comparator | Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. Receives: Dietary Supplement: Geranylgeraniol (300 mg) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Leg Press One-Repetition Maximum (1RM)
Maximal lower-body strength will be assessed as leg press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Measured: Change from baseline (Week 0) to Week 8
Bench Press One-Repetition Maximum (1RM)
Maximal upper-body strength will be assessed as bench press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Measured: Change from baseline (Week 0) to Week 8
Fat-Free Mass
Fat-free mass will be assessed using a four-compartment body composition model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Secondary outcomes (15)
Leg Press Muscular Endurance
Lower-body muscular endurance will be assessed as the number of repetitions completed to failure on the leg press using a load corresponding to 80% of the participant's baseline leg press 1RM.
Measured: Change from baseline (Week 0) to Week 8
Bench Press Muscular Endurance
Upper-body muscular endurance will be assessed as the number of repetitions completed to failure on the bench press using a load corresponding to 80% of the participant's baseline bench press 1RM.
Measured: Change from baseline (Week 0) to Week 8
Peak Oxygen Consumption (VO2peak)
Aerobic capacity will be assessed as peak oxygen consumption (VO2peak) during a graded treadmill exercise test.
Measured: Change from baseline (Week 0) to Week 8
Fat Mass
Fat mass will be assessed using dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Percent Body Fat
Percent body fat will be assessed using dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Total Body Water
Total body water will be assessed using bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Intracellular Water
Intracellular water will be assessed using bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Extracellular Water
Extracellular water will be assessed using bioelectrical impedance spectroscopy (BIS).
Measured: Change from baseline (Week 0) to Week 8
Plasma Coenzyme Q10 Concentration
Plasma coenzyme Q10 concentration will be assessed from venous blood samples.
Measured: Change from baseline (Week 0) to Week 8
Serum Testosterone Concentration
Serum testosterone concentration will be assessed from venous blood samples.
Measured: Change from baseline (Week 0) to Week 8
Serum Estrogen Concentration
Serum estrogen concentration will be assessed from venous blood samples.
Measured: Change from baseline (Week 0) to Week 8
Serum Progesterone Concentration
Serum progesterone concentration will be assessed from venous blood samples.
Measured: Change from baseline (Week 0) to Week 8
Profile of Mood States (POMS) Score
Mood state will be assessed using the Profile of Mood States (POMS) questionnaire.
Measured: Change from baseline (Week 0) to Week 8
RAND SF-36 Score
Health-related quality of life will be assessed using the RAND SF-36 questionnaire.
Measured: Change from baseline (Week 0) to Week 8
Fecal Metabolomic Profile
Fecal metabolomic outcomes will be assessed from self-collected stool samples.
Measured: Change from baseline (Week 0) to Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2026
- Study start3 Mar 2025
- Primary completion1 Aug 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Muscle HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized to one of three parallel groups to receive either placebo, 150 mg geranylgeraniol (GG), or 300 mg geranylgeraniol (GG) daily for 8 weeks. Randomization will be stratified by sex, age, and baseline fat-free mass. All groups will follow the same testing schedule and procedures throughout the study period.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lindenwood University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chad M Kerksick, PhD, Principal investigator, Lindenwood University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07502924
- Sponsor's protocol ID
- IRB-25-35
- Acronym
- GGE
- Status last verified
- Mar 2026
- First submitted
- 25 Mar 2026
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscular Strength, Body Composition, Sex Steroid Hormones and CoQ10 Levels in Healthy Men and Women
- ClinicalTrials.gov ID
- NCT07502924
- Acronym / sponsor ID
- GGE / IRB-25-35
- Conditions
- Muscle Health, Muscle Strength, Body Composition
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Lindenwood UniversityUniversity, hospital or other
- Study start
- 3 Mar 2025 (actual)
- Primary completion
- 1 Aug 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 31 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.
Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
Detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-group trial designed to examine the dose-response effects of geranylgeraniol (GG) supplementation on muscular strength, body composition, aerobic capacity, and physiological biomarkers in healthy, physically active adults.
Approximately 60 men and women aged 30-60 years will be recruited and randomized, stratified by sex, age, and baseline fat-free mass, to receive one of three interventions: placebo, 150 mg GG, or 300 mg GG daily for 8 weeks. All participants and study personnel will remain blinded to group allocation throughout the study.
Participants will complete a screening visit followed by testing visits at baseline (week 0), week 4, and week 8. Assessments will include maximal strength testing (1RM bench press and leg press), muscular endurance (repetitions to failure at a fixed percentage of 1RM), aerobic capacity (VO2peak via graded treadmill test), and body composition using a four-compartment model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy.
Venous blood samples will be collected to assess coenzyme Q10, sex steroid hormones, inflammatory markers, and clinical safety parameters including complete blood count, comprehensive metabolic panel, and lipid profile. Additional outcomes include mood and quality of life assessed via validated questionnaires (POMS and SF-36), dietary intake via 4-day food logs, and fecal samples for metabolomic analysis.
The primary endpoints are changes in maximal strength (1RM leg press and bench press) and fat-free mass from baseline to week 8. Secondary endpoints include changes in muscular endurance, aerobic capacity, body composition variables, biochemical markers, and patient-reported outcomes. Safety will be monitored throughout the study via clinical labs and adverse event reporting.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Participants will be randomized to one of three parallel groups to receive either placebo, 150 mg geranylgeraniol (GG), or 300 mg geranylgeraniol (GG) daily for 8 weeks. Randomization will be stratified by sex, age, and baseline fat-free mass. All groups will follow the same testing schedule and procedures throughout the study period.
| Arm | Type | Receives |
|---|---|---|
| Placebo Comparator | Placebo comparator | Dietary Supplement: Dietary Supplement - PlaceboParticipants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. |
| 150 mg Geranylgeraniol | Active comparator | Dietary Supplement: Geranylgeraniol (150 mg)Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. |
| 300 mg Geranylgeraniol | Active comparator | Dietary Supplement: Geranylgeraniol (300 mg)Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Between 30 and 60 years old.
- Body mass index values will range from >18.5 and <29.9 kg/m2
- Subject agrees to maintain their existing dietary patterns throughout the study period.
- Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.
- Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week.
Key exclusion criteria (22 listed)
- BMI <18.5 or > 29.9 kg/m2
- Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV/AIDS), or neurological condition or disease.
- Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.
- History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
- Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary Supplement - PlaceboParticipants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. | Dietary supplement | Placebo Comparator |
| Geranylgeraniol (150 mg)Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. | Dietary supplement | 150 mg Geranylgeraniol |
| Geranylgeraniol (300 mg)Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day. | Dietary supplement | 300 mg Geranylgeraniol |
Primary outcome
Leg Press One-Repetition Maximum (1RM)
Time frame: Change from baseline (Week 0) to Week 8
Maximal lower-body strength will be assessed as leg press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Bench Press One-Repetition Maximum (1RM)
Time frame: Change from baseline (Week 0) to Week 8
Maximal upper-body strength will be assessed as bench press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Fat-Free Mass
Time frame: Change from baseline (Week 0) to Week 8
Fat-free mass will be assessed using a four-compartment body composition model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
15 secondary outcomes
Leg Press Muscular Endurance
Time frame: Change from baseline (Week 0) to Week 8
Bench Press Muscular Endurance
Time frame: Change from baseline (Week 0) to Week 8
Peak Oxygen Consumption (VO2peak)
Time frame: Change from baseline (Week 0) to Week 8
Fat Mass
Time frame: Change from baseline (Week 0) to Week 8
Percent Body Fat
Time frame: Change from baseline (Week 0) to Week 8
Total Body Water
Time frame: Change from baseline (Week 0) to Week 8
Intracellular Water
Time frame: Change from baseline (Week 0) to Week 8
Extracellular Water
Time frame: Change from baseline (Week 0) to Week 8
Plasma Coenzyme Q10 Concentration
Time frame: Change from baseline (Week 0) to Week 8
Serum Testosterone Concentration
Time frame: Change from baseline (Week 0) to Week 8
Serum Estrogen Concentration
Time frame: Change from baseline (Week 0) to Week 8
Serum Progesterone Concentration
Time frame: Change from baseline (Week 0) to Week 8
Profile of Mood States (POMS) Score
Time frame: Change from baseline (Week 0) to Week 8
RAND SF-36 Score
Time frame: Change from baseline (Week 0) to Week 8
Fecal Metabolomic Profile
Time frame: Change from baseline (Week 0) to Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
Related trials for Muscle Health
Not yet recruiting
Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers
Lung Carcinoma
Recruiting
Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients
Mobility Limitation, Frailty
Not yet recruiting
Radiofrequency and Pelvic Floor Exercise for Primary Dysmenorrhea
Primary Dysmenorrhea
Not yet recruiting
Acute Effects of High-Intensity Laser Therapy on Pain, Muscle Stiffness, and Grip Strength in Healthy Adults
Exercise-Induced Muscle Fatigue, Fatigue Recovery
Not yet recruiting
Neuromuscular Electrical Stimulation to Improve the Muscle Health of Individuals With Acute Kidney Injury
Acute Kidney Injury, Acute Kidney Injury KDIGO 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chad M Kerksick, PhD principal investigator
Lindenwood University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Geranylgeraniol (150 mg) and Geranylgeraniol (300 mg) in people with Muscle Health and Muscle Strength, run by Lindenwood University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anthony M Hagele, MS (6369494785, ahagele@lindenwood.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Leg Press One-Repetition Maximum (1RM) (time frame: Change from baseline (Week 0) to Week 8). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.